CHENGDU, Chine, 10 juin 2023 /PRNewswire/ — Le 8 juin 2023, le vaccin protéique Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) (cellule Sf9) développé par WestVac Biopharma/ West China Medical Center, Sichuan University a été approuvé pour une…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.